Dr. Michele Carbone received the 2026 Szent-Görgyi Prize for his groundbreaking discovery that mesothelioma can be transmitted through families in a Mendelian fashion, driven by inherited mutations in the BAP1 gene. His research has transformed how the disease is understood, diagnosed, treated and prevented worldwide.
Sujuan Ba, CEO of the National Foundation for Cancer Research, has been recognized as one of OncoDaily's 100 Most Influential CEOs in Oncology in 2025. Under her leadership, NFCR has strengthened its role as a strategic accelerator of cancer research, supporting innovative science and fostering cross-sector collaboration.
Dr. Brian Leyland-Jones was a renowned breast cancer oncologist and translational research leader who played a pivotal role in advancing cancer therapies. He made himself available to patients in need, offering his expertise pro bono and guiding them through diagnoses and treatment options.
Artificial intelligence is transforming cancer prevention, detection, and treatment by connecting technology with people. AI-driven public-health analytics, patient-doctor relationships, and diverse clinical research are crucial for delivering immediate benefit to patients, clinicians, and policymakers.
The 2025 NFCR Global Summit will convene world-renowned experts in cancer research, entrepreneurship, and patient care. Keynote speakers include Monica Bertagnolli, Webster K. Cavenee, Lisa Coussens, Ronald DePinho, and Tony Hunter.
A research team has developed a powerful software that simulates cancer cell behavior, allowing scientists to model tumor growth, immune responses, and treatment outcomes in a virtual setting. This technology enables researchers to explore treatment options alongside lab models and clinical trials, without the cost or risk to patients.
Dr. Tony Hunter has made a groundbreaking discovery in cancer research, revealing the process of tyrosine phosphorylation that transformed cancer treatment. His work has led to the development of targeted therapies using tyrosine kinase inhibitors, saving millions of lives worldwide.
Dr. Robert C. Bast, Jr., a pioneer in cancer science, receives the AACR-Daniel D. Von Hoff Award for his decades-long dedication to nurturing the next generation of cancer research leaders. His groundbreaking discoveries have saved countless lives and transformed ovarian cancer detection and management.
Dr. Rakesh Jain has received the AACR Lifetime Achievement Award for his groundbreaking theory of vascular normalization, which challenged conventional wisdom in antiangiogenic therapies. His work has directly contributed to FDA approval of several drug combinations, enhancing outcomes for patients with various cancers.
The National Foundation for Cancer Research (NFCR) has launched a new podcast called All Things Cancer. The podcast is hosted by Sujuan Ba, Ph.D., and features conversations with leading scientists, oncologists, doctors, patient advocates, caregivers, biotech innovators, and survivors.
The National Foundation for Cancer Research has announced the winners of its 2021 Salisbury Award Competition, recognizing promising cancer research innovations. The first prize winner is TanoMed's technology training host immunity against a specific member of the carcinoembryonic antigen-related cell adhesion molecule family, CEACAM5.
YIV-906, a first-in-class botanical drug candidate developed through NFCR funding, commences Phase IIB clinical trials for hepatitis B-associated liver cancer. The drug has demonstrated safety and promising efficacy in early-stage trials and may improve survival and quality of life for patients.
A drug delivery candidate technology has been approved by the FDA for human clinical trials to treat T-cell non-Hodgkin's lymphoma. The technology, developed with an NFCR grant, addresses the challenge of delivering a cancer-mitigating compound, fenretinide, in adequate doses to tumor cells.
A NFCR-funded translational cancer research project has been awarded a $700,000 Virginia Catalyst grant to advance its lead cancer drug candidate. The funding will support collaboration among VCU, UVA, and ILCT to commercialize and bring to patients novel therapeutic treatments targeting metastatic cancers.
The National Foundation for Cancer Research has named the winners of its Salisbury Award Competition, recognizing innovative cancer research projects. The winning project, led by Emily Han-Chung Hsiue and Jacqueline Douglass, targets cancer driver mutations with a novel antibody-based method.
Susan Band Horwitz, an NFCR fellow, has been named a Giant of Cancer Care for her pioneering work on Taxol and its role in stabilizing microtubules to prevent cancer cell growth. Her research enabled the development of life-saving medications for ovarian, breast, and lung cancers.
The National Foundation for Cancer Research (NFCR) has launched the Salisbury Award, a new program aimed at supporting translational cancer research. The award will provide funding and resources to researchers with early-stage projects deemed to have the best combination of novel and impactful technology.
The National Foundation for Cancer Research has received a $35,000 grant from Safeway Foundation to expand its Cancer Patient Navigation Hotline services. The hotline provides guidance and support to patients and their families at no cost, aiming to equip users with knowledge enabling better decisions about their cancer care.
Researchers have discovered a link between MUC16 gene mutations and higher tumor mutation loads in gastric cancer patients, which may improve response rates to immunotherapy. The study's findings could open up new treatment options for up to 38% of gastric cancer patients.
A quartet of NFCR scientists publishes papers on possible bases for brain cancer treatments and insight into somatic mutations, advancing understanding of glioblastoma multiforme and its resistance to anti-angiogenesis drugs. The findings also identify a potential therapeutic strategy using MDA-9/Syntenin.
Research funded by NFCR finds two distinct patterns of metastatic spread in human colorectal cancer, where distant metastases originate directly from primary tumors without involving the lymph system. The study provides genetic evidence towards resolving the enigma of lymph node metastases and distant metastases.
Researchers have discovered a novel mechanism behind treatment resistance in brain metastatic breast cancers, and a potential treatment strategy that may overcome this resistance. Targeting the Human Epidermal Growth Factor Receptor 3 (HER3) protein has been shown to significantly slow tumor growth and improve survival.
Researchers from the National Foundation for Cancer Research (NFCR) have discovered a new pharmacological agent to treat glioblastoma multiforme, a deadly brain cancer. The treatment has shown profound survival benefits in pre-clinical models when combined with radiation.
Researchers identified a unique oscillating pattern of a key cancer gene that may contribute to disease progression and treatment resistance. The study found that simultaneous treatment with chemotherapy and targeted drugs can suppress tumor cell growth in both ER+/HER2- and HER2+ subpopulations.
Chinese Minister of Health Dr. Zhu Chen will hold talks with leading cancer researchers from the US and China to develop a stronger platform for Sino-US research collaboration. The goal is to fast-track cancer research and create deeper ties among researchers.
Peter K. Vogt's groundbreaking discovery of src, the first cancer-causing gene, has profoundly changed biology and medicine. His research has yielded several important targets in cancer therapy.
Dr. Harold F. Dvorak, M.D.'s groundbreaking work on vascular permeability factor/vascular endothelial cell growth factor (VEGF) has led to significant clinical benefits in cancer patients. His discovery has enabled the development of anti-VEGF therapies with outstanding clinical antitumor activity.
The Albert Szent-Györgyi Prize is awarded to researchers making notable contributions to cancer prevention, diagnosis, and treatment. The $25,000 cash award promotes public awareness of basic science cancer research and encourages increased investment in cancer research.